Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes, a test-negative study in Quebec, Canada

The Lancet Regional Health - Americas 2026 Open access

Read full text
Authors: Sara Carazo, Manale Ouakki, D M Skowronski, Maude Paquette, Nicholas Brousseau, Denis Talbot, Charles-Antoine Guay, Caroline Quach, Rodica Gilca, Jesse Papenburg
DOI: 10.1016/j.lana.2026.101448
Cited by: 4
References: 26

Abstract

Background: In 2024-25, Quebec implemented a universally publicly funded infant nirsevimab program. We estimated effectiveness, number-needed-to-immunize (NNI) and impact against severe respiratory syncytial virus (RSV) outcomes. Methods: A test-negative study estimated adjusted effectiveness among nirsevimab-eligible children RSV-tested during emergency room (ER) consultation or hospitalization between October 2024 and March 2025. Eligible children were born during the RSV season (at-birth group) or

Fields of Study & Subjects

Respiratory viral infections research Viral Infections and Immunology Research Multiple Sclerosis Research Studies

Publication details

Journal / source
The Lancet Regional Health - Americas
Publisher
Elsevier BV
Volume
57
Pages
101448–101448
Publication date
11 March 2026
Language
EN